Canadian contract services group Patheon will roll out a cell based assay offering that it says will help the biopharmaceutical sector advance the development of the next generation of biologic drugs.
WuXi PharmaTech’s operating income fell by 25 per cent in Q1, in part because of an 81 per cent drop in revenues from manufacturing, but the company reconfirmed its 2009 financial guidance.
US non-clinical contract research firm Wil Research Laboratories has reduced its 700 strong workforce by 4 per cent, citing a drop in business due to the global economic downturn as the basis for the cuts.
AstraZeneca (AZ) has become the latest company to enter into a research collaboration with Jubilant, with the companies initially focusing on delivering preclinical candidates in the neuroscience area.
Charles River Laboratories (CRL) has bucked the CRO sector trend and reaffirmed its forecasts for 2009, citing an improved order book and better pricing as the reasons for its relative optimism.
Epistem claims its “plucked hair biomarker model” provides drugmakers with minimally invasive way monitoring epithelial response to cancer candidates that can significantly reduce development times.
The past few days have seen a string of announcements from contract research organisations (CROs) which indicate that their appetite for international expansion and development remains unsated.
Just weeks after expanding its relationship with AstraZeneca, Chinese CRO BioDuro has been asked by Swiss drug major Roche to help with its discovery phase R&D programme.
ReSearch Pharmaceutical Services has expanded its activities into the Asian market via the purchase of Chinese contract research organisation (CRO) Paramax International.
Contract research organisation PPD has boosted its compound partnering programme with the purchase of dermatology specialist Magen BioSciences, and divested its presclinical research subsidiary Pedmont Research Centre.
Chinese contract research provider WuXi PharmaTech slipped to a fourth quarter loss in 2008, despite reporting a strapping 74 per cent increase in sales.
Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.
Porsolt, a French contract research organisation (CRO) specialising in preclinical pharmacology services, has said it plans to open a new facility in Europe as well as boost its presence on the other side of the Atlantic.
SGS Life Science Services opened a new microbiology testing laboratory in Shanghai, China to offer cGMP compliant API testing services for method development and validation.
Belgian biopharmaceutical company UCB has contracted Proteros Biostructures of Germany to provide support in the structure-based discovery of small-molecule drugs.
An undercover investigation at a primate centre that conducts preclinical research has raised allegations of routine and unlawful mistreatment of the apes and wastage of taxpayers’ money.
With M&A activity dominating Big Pharma's agenda at the moment, the contract research market is having to evolve and adapt to the turbulent environmnet. Outsourcing-pharma asked Frost & Sullivan analyst Barath Shankar to offer his opinion...
UK contract services provider Melbourn Scientific has extended its service portfolio, predicting that demand for outsourced early R&D will increase in times of economic gloom.
Two UK-based companies, PRECOS and Argenta Discovery, have pooled their resources in the area of cancer drug discovery to provide services spanning “from hit finding to in vivo proof-of-concept.”
WIL Research Laboratories has expanded into protein and small molecule bioanalysis and genetic toxicology through the acquisition of Midwest BioResearch.
UK company Celsis saw softness in demand across its operating divisions in the third quarter ended December 31, and said it was considering “strategic alternatives” for its laboratory services unit.
Charles River Laboratories will reduce its workforce by 3 per cent, close its preclinical facility in Arkansas, US and sell off its Phase I trial site in Edinburgh, Scotland as part of a cost reduction programme.
Seattle, US-based Cell Therapeutics Inc is looking at ways to reduce its involvement in a preclinical research facility based in Bresso, Italy, as it tries to cut costs.
A team of US scientists have assembled clusters of cells into living ‘microtissues’ as part of a programme aimed initially at reducing the use of animal models in early-stage drug development.
US contract development firm Azopharma has begun offering microdosing at its AvivoClin facility in Daytona Beach, Florida, joining market leaders like Xeleron and Covance in the Phase 0 trial sector.
The world’s largest contract research organisation, Covance, has maintained its earnings guidance for 2009 despite a slowdown in revenue growth and lower profits in the fourth quarter of 2008.
Contract research firm Covance has been given the green light for its $100m (€77m) animal testing and drug candidate development facility in Chandler, Arizona, US.
Indian contract research firm Jubilant Biosys has teamed up with US company BioLeap to offer drug early-stage discovery services which incorporate computational drug design.
Contract research organization Pharmaceutical Product Development Inc (PPD) has moved further into providing central laboratory services with the purchase of a 130,000 sq. ft. laboratory from Merck & Co.
WuXi AppTec is to use ThalesNano’s H-Cube for laboratory-based hydrogenation, which the CRO believes offers advantages in drug discovery over traditional batch processes.
Blue Reference has formed a Quality by Design Product Development Consortium (QbD PDC) to provide a forum for the improvement of its process analytics software.
Simple preclinical experiments should be able to predict whether immunotherapeutic medicines are safe to advance to preclinical testing in humans and avoid the Northwick Park trial that left six healthy volunteers hospitalised.
US contract research company MPI Research is laying off around 200 employees, but will still end the year with a higher headcount as it takes over two former Pfizer offices, according to local news reports.
Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
Applied Cytometry (AC) hopes its VenturiOne v3 software, which is capable of processing 400 files in under 10 seconds, will win over drug developers looking to expedite large-scale laboratory analysis.
The US CRO market is predicted to have a healthy future, with the greatest potential for growth in the preclinical sector, according to a report by Frost & Sullivan.
UK company ProImmune has launched a suite of services to help drugmakers determine at an early stage whether a biologic drug will elicit an immune response in humans.
US company Smithers Group has launched a formulation services company to tap into the emerging trend towards outsourcing of drug development among pharmaceutical companies.
Covance has defied challenging market conditions and posted positive results for the third quarter, with the company believing more major R&D outsourcing contracts are a possibility.
Increasing bureaucracy in clinical research in the UK is posing a threat to the industry, according to a report published in the British Medical Journal.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Johnson & Johnson has tapped Chinese WuXi PharmaTech for additional R&D services, following the trend towards high-level, strategic collaborations between drugmakers and contract research organisations.
Tepnel Life Sciences has expanded its pharmaceutical services offering by becoming the UK’s first genetic analysis services provider to use Illumina’s next-generation iScan system.
The use of internal standards (IS) is essential for developing and applying liquid chromatography-tandem mass spectrometric (LC-MS/MS) quantitative bioanalytical...
Global regulatory standards govern bioanalytical method development, validation and the subsequent assays. When those standards are updated, industry stakeholders...
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...
